
This episode covers the importance of considering vaccine timing, selection, and hesitancy in patients on immunomodulating and immunosuppressive therapies, along with emerging data linking several vaccines to reduced dementia risk.

This episode covers the importance of considering vaccine timing, selection, and hesitancy in patients on immunomodulating and immunosuppressive therapies, along with emerging data linking several vaccines to reduced dementia risk.

Guest Jenelle Montgomery, PharmD, BCACP, CPP, joins Erica Marini to review key updates from the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting.

Erica Marini, PharmD, MS, BCPS; and Millad Sobhanian, PharmD, BCPS, unpack Auvelity's approval, efficacy data, and safety profile for treating agitation in Alzheimer disease.

Erica Marini, PharmD, MS, BCPS, the host of "Mind the Meds," discusses the show's format, guest conversations, and upcoming episodes covering CAR T therapy and a Consortium of Multiple Sclerosis Centers Annual Meeting roundup.

Guests Adrian Wong, PharmD, MPH, BCCCP; and Cayley Krkljes, PharmD, BCPS, about a systematic review of phenobarbital and primidone drug-drug interactions, highlighting clinically significant risks when used with other therapies.

Erica Marini, PharmD, MS, BCPS; and guest Millad Sobhanian, PharmD, BCPS, discuss 3 major Alzheimer disease developments: a newly approved agitation therapy, the delayed FDA decision on lecanemab subcutaneous initiation dosing, and a controversial review on antiamyloid therapies.

In this debut episode Erica Marini and her colleagues discuss the critical role pharmacists play in complex neurologic care and the latest emerging therapies and research presented at the AAN 2026 Annual Meeting.

This new podcast will explore therapies, trends, and clinical decisions shaping neurology from a pharmacist's point of view.

April 27th 2026